Psylin Neurosciences Inc., a joint venture biotechnology company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. announced that it has initiated IND-enabling development of a novel compound, PSN0041, for the treatment of depression. PSN0041, a peptide from Amylin’s proprietary polypeptide hormone library, PHORMOL, was identified as having utility in depression after screening it in PsychoGenics’ proprietary, drug discovery technologies.
Popularity: unranked [?]
